Everything below concerns GIP receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Degtyarenko K, Fábián P. "Directory of P450-containing Systems". International Centre for Genetic Engineering and Biotechnology (ICGEB). Archived from the original on 2016-07-16. Gao J, Ellis LB, Wackett LP. "Biocatalysis/Biodegradation Database". University of Minnesota. Archived from the original on 2012-05-30. "Substrate Product Occurrence Ratio Calculator (SPORCalc)". Archived from the original on 2009-03-18. Microbial biodegradation
Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). It is an interleukin 13 antagonist. It is given by subcutaneous injection. The most common side effects include injection site reactions, dry eye and conjunctivitis, including allergic conjunctivitis. Lebrikizumab was approved for medical use in the European Union in November 2023, in Canada in June 2024, and in the US in September 2024.
While the "ness team" began moving to Bawdsey, the Orfordness site remained in use. This proved useful during one demonstration when the new system recently completed at Bawdsey failed. The next day, Robert Hanbury-Brown and the new recruit Gerald Touch started up the Orfordness system and were able to run the demonstrations from there. The Orfordness site was not closed until 1937.
One should expect that, within a few thousand years of its entering the stage of industrial development, any intelligent species should be found occupying an artificial biosphere which surrounds its parent star. Dyson conceived that such structures would be clouds of asteroid-sized space habitats, though science fiction writers have preferred a solid structure: either way, such an artifact is often called a Dyson sphere, although Dyson used the term "shell". Dyson said that he used the term "artificial biosphere" in the article to mean a habitat, not a shape. The general concept of such an energy-transferring shell had been created decades earlier by science fiction writer Olaf Stapledon in his 1937 novel Star Maker, a source which Dyson credited publicly. Freeman Dyson was interviewed by Robert Wright in 2003 and the Dyson Sphere topic was broached. In response he stated that the paper he wrote on this concept was intended to be a joke and had nothing to do with work. He added that it amused him that he had become famous only for the things he didn't think were serious.
H2NCO−2 + 2 H2O ⇌ NH+4 + HCO−3 + OH− H2NCO−2 + H2O ⇌ NH+4 + CO2−3 Calcium carbamate is soluble in water, whereas calcium carbonate is not. Adding a calcium salt to an ammonium carbamate/carbonate solution will precipitate some calcium carbonate immediately, and then slowly precipitate more as the carbamate hydrolyzes.
Sources: en.wikipedia.org
=== Sara Dhadwal === Sara Dhadwal (Priyanga Burford) is the president of Pierpoint London in series 1, and oversees its new hire program. Firm and principled, she initially clashes with Gus Sackey when he castigates her for promoting Pierpoint's cutthroat culture, which he blames for the death of his colleague Hari Dhar. However, Sara gradually becomes more in favor of culture change at the company; she views Eric as the primary embodiment of Pierpoint's toxicity, and fires him after Harper reports Eric locking her in a conference room to berate her. She also tries to become a more supportive figure to Gus, but he grows increasingly disillusioned with the firm, and purposely sabotages his interview on reduction-in-force (RIF) day. The same day, Pierpoint's global head of FICC, Bill Adler, offers Harper a chance to retract her complaint against Eric to bring him back to the firm; Sara takes her aside and tries talking her out of it, telling her she has the power to fundamentally change the culture of Pierpoint. Harper, however, rebuffs Sara for seeing her as a victim, and agrees to have Eric rehired.
L-RNA aptamers, built using L-ribose, are the enantiomers of natural oligonucleotides, which are made with D-ribose. Nucleic acid aptamers, including L-RNA aptamers, contain adenosine monophosphate, guanosine monophosphate, cytidine monophosphate, uridine monophosphate, a phosphate group, a nucleobase and a ribose sugar.
In physics, a vapor (American English) or vapour (Commonwealth English; see spelling differences) is a substance in the gas phase at a temperature lower than its critical temperature, which means that the vapor can be condensed to a liquid by increasing the pressure on it without reducing the temperature of the vapor. A vapor is different from an aerosol. An aerosol is a suspension of tiny particles of liquid, solid, or both within a gas. For example, water has a critical temperature of 647 K (374 °C; 705 °F), which is the highest temperature at which liquid water can exist at any pressure. In the atmosphere at ordinary temperatures gaseous water (known as water vapor) will condense into a liquid if its partial pressure is increased sufficiently. A vapor may coexist with a liquid (or a solid). When this is true, the two phases will be in equilibrium, and the gas-partial pressure will be equal to the equilibrium vapor pressure of the liquid (or solid).
The cellular response in signal transduction cascades involves alteration of the expression of effector genes or activation/inhibition of targeted proteins. Regulation of protein activity mainly involves phosphorylation/dephosphorylation events, leading to its activation or inhibition. It is the case for the vast majority of responses as a consequence of the binding of the primary messengers to membrane receptors. This response is quick, as it involves regulation of molecules that are already present in the cell. On the other hand, the induction or repression of the expression of genes requires the binding of transcriptional factors to the regulatory sequences of these genes. The transcriptional factors are activated by the primary messengers, in most cases, due to their function as nuclear receptors for these messengers. The secondary messengers like DAG or Ca2+ could also induce or repress gene expression, via transcriptional factors. This response is slower than the first because it involves more steps, like transcription of genes and then the effect of newly formed proteins in a specific target. The target could be a protein or another gene.
Sources: en.wikipedia.org
==== Direct recycling ==== Direct recycling is the removal of the cathode or anode from the electrode, which are then reconditioned and reused in a new battery. Mixed metal-oxides can be added to the new electrode with very little change to the crystal morphology. The process generally involves the addition of new lithium to replenish the loss of lithium in the cathode due to degradation from cycling. Cathode strips are obtained from the dismantled batteries, then soaked in NMP, and undergo sonication to remove excess deposits. It is treated hydrothermally with a solution containing LiOH/Li2SO4 before annealing. This method is extremely cost-effective for noncobalt-based batteries as the raw materials do not make up the bulk of the cost. Direct recycling avoids the time-consuming and expensive purification steps, which is great for low-cost cathodes such as LiMn2O4 and LiFePO4. For these cheaper cathodes, most of the cost, embedded energy, and carbon footprint is associated with the manufacturing rather than the raw material. It is experimentally shown that direct recycling can reproduce similar properties to pristine graphite. The drawback of the method lies in the condition of the retired battery. In the case where the battery is relatively healthy, direct recycling can cheaply restore its properties. However, for batteries where the state of charge is low, direct recycling may not be worth the investment. The process must also be tailored to the specific cathode composition, and therefore the process must be configured to one type of battery at a time.
** Indicates an Imperial Fortress † Bermuda and Halifax were linked, under the Commander-in-Chief at Halifax, with units and strength at Bermuda included in figures for Halifax In February 1855 the new Secretary of State for War was additionally commissioned as Secretary at War, thus giving the Secretary of State oversight of the War Office in addition to his own department. The same procedure was followed for each of his successors, until the office of Secretary at War was abolished altogether in 1863. In 1855 the Board of Ordnance was abolished as a result of its perceived poor performance during the Crimean War. This powerful independent body, dating from the 15th century, had been directed by the Master-General of the Ordnance, usually a very senior military officer who (unlike the Secretary at War) was often a member of the Cabinet. The disastrous campaigns of the Crimean War resulted in the consolidation of all administrative duties in 1855 as subordinate to the Secretary of State for War, a Cabinet job. He was not, however, solely responsible for the Army; the Commander-in-Chief had a virtually equal degree of responsibility. This was reduced in theory by the reforms introduced by Edward Cardwell in 1870, which subordinated the Commander-in-Chief to the Secretary for War. In practice, however, a large influence was retained by the conservative Commander-in-Chief Field Marshal Prince George, 2nd Duke of Cambridge, who held the post between 1856 and 1895.
== Discovery == In 2004 Linda B. Buck and Richard Axel won the Nobel Prize in Physiology or Medicine for their work on olfactory receptors. In 2006, it was shown that another class of odorant receptors – known as trace amine-associated receptors (TAARs) – exist for detecting volatile amines. Except for TAAR1, all functional TAARs in humans are expressed in the olfactory epithelium. A third class of olfactory receptors known as vomeronasal receptors has also been identified; vomeronasal receptors putatively function as pheromone receptors. As with many other GPCRs, there is still a lack of experimental structures at atomic level for olfactory receptors and structural information is based on homology modeling methods. In 2023 the structure of OR51E2 was found, the first elucidation of the structure of any human olfactory receptor. The limited functional expression of olfactory receptors in heterologous systems, however, has greatly hampered attempts to deorphanize them (analyze the response profiles of single olfactory receptors) This was first completed by genetically engineered receptor, OR-I7 to characterize the "odor space" of a population of native aldehyde receptors.
TGF beta 1 – TGFB1 TGF beta 2 – TGFB2 TGF beta 3 – TGFB3 A fourth member of the subfamily, TGFB4, has been identified in birds and a fifth, TGFB5, only in frogs. The peptide structures of the TGF-β isoforms are highly similar (homologies on the order of 70–80%). They are all encoded as large protein precursors; TGF-β1 contains 390 amino acids and TGF-β2 and TGF-β3 each contain 412 amino acids. They each have an N-terminal signal peptide of 20–30 amino acids that they require for secretion from a cell, a pro-region called latency-associated peptide (LAP - Alias: Pro-TGF beta 1, LAP/TGF beta 1), and a 112-114 amino acid C-terminal region that becomes the mature TGF-β molecule following its release from the pro-region by proteolytic cleavage. The mature TGF-β protein dimerizes to produce a 25 KDa active protein with many conserved structural motifs. TGF-β has nine cysteine residues that are conserved among its family. Eight form disulfide bonds within the protein to create a cysteine knot structure characteristic of the TGF-β superfamily. The ninth cysteine forms a disulfide bond with the ninth cysteine of another TGF-β protein to produce a dimer. Many other conserved residues in TGF-β are thought to form secondary structure through hydrophobic interactions. The region between the fifth and sixth conserved cysteines houses the most divergent area of TGF-β proteins that is exposed at the surface of the protein and is implicated in receptor binding and specificity of TGF-β.
The need for an international standard for chemistry was first addressed in 1860 by a committee headed by German scientist Friedrich August Kekulé von Stradonitz. This committee was the first international conference to create an international naming system for organic compounds. The ideas that were formulated at that conference evolved into the official IUPAC nomenclature of organic chemistry. IUPAC is a legacy of this meeting, making it one of the most important historical international collaborations of chemistry societies. IUPAC as such was established in 1919.Since this time, IUPAC has been the official organization with the responsibility of updating and maintaining official organic nomenclature. One notable country excluded from early IUPAC was Germany. Germany's exclusion was a result of prejudice towards it by the Allied powers after World War I. Germany was finally admitted into IUPAC in 1929. However, Nazi Germany was removed from IUPAC during World War II. At this time, IUPAC was affiliated with the Allied powers, but had little involvement with the war effort itself. East and West Germany were only readmitted to IUPAC in 1973. Since World War II, IUPAC has focused on standardizing nomenclature and methods in science. In 2016, IUPAC denounced the use of chlorine as a chemical weapon. In a letter to Ahmet Üzümcü, director of the Organisation for the Prohibition of Chemical Weapons (OPCW), the organization pointed out their concerns in regards to chlorine weapon usage in the Syrian civil war and other places .
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.